This installment in our joint-accredited educational series on the management of venous thromboembolism addresses risk assessment and the overlapping risk factors and prevalence considerations for VTE. Thrombosis researcher, Charles Pollack, MD, works through the complex data on individual and additive risk concerns and how those contribute to there now being an overall prevalence of 1 in 12 adults globally experiencing at least one VTE event during their lifetime.
Primary care physicians, internists, family medicine physicians, allied healthcare professionals and other healthcare providers involved in the care of patients with VTE.
Review strategies for prevention, risk assessment, and incidence in the management of patients with VTE
VTE: Prevention, Risk Assessment, and Incidence
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.
| Faculty | Relationship Identified With: |
| Charles V. Pollack Jr., MD | Consultant/Advisor: AstraZeneca Pharmaceuticals; Anthos Therapeutics; Milestone Pharmaceuticals; Huyabio; Provepharm US Grant/Research Support: Provepharm US |
Timothy Hayes, MD, PhD; Charles V. Pollack Jr., MD; Kim Cheramie, MSN, RN-BC; Patrick Hayes and Nicole McMenamin hereby state that they do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM.
AcademicCME designates this enduring material for a maximum of 0.75 CNE Contact Hours.
AcademicCME designates this continuing education activity for 0.75 CPE Contact Hours (0.075 CEUs) of continuing pharmacy education credit (UAN # JA4008190-0000-24-002-H01-P.)
Learners should only claim credit commensurate with the extent of their participation.
This activity has been supported by an independent educational grant from the Bristol Myers Squibb and Pfizer Alliance.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and the Bristol Myers Squibb and Pfizer Alliance do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to claim credit, participants must complete the following:
For all CE inquiries or special needs, please contact admin@academiccme.com.
